IP Library Granted Patent US 7,375,197
Granted Patent B2
US 7,375,197 · App. 10/031,496 · Granted May 20, 2008

Cellobiohydrolase I gene and improved variants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,375,197
App. No.
10/031,496
Granted
May 20, 2008
Kind
B2
Abstract

The disclosure provides a method for preparing an active exoglucanase in a heterologous host of eukaryotic origin. The method includes mutagenesis to reduce glycosylation of the exoglucanase when expressed in a heterologous host. It is further disclosed a method to produce variant cellobiohydrolase that is stable at high temperature through mutagenesis.

Claims (28)

1. A nucleic acid molecule having a nucleic acid sequence encoding a variant cellobiohydrolase mutated with respect to a wild-type cellobiohydrolase represented by SEQ ID NO: 99, the mutation providing means for improving cellobiohydrolase functionality with respect to the wild-type cellobiohydrolase functionality, wherein the functionality is thermostability, enzymatic activity, catalytic activity, product inhibition, glycosylation, and/or peptide strain.

2. The nucleic acid molecule of claim 1 wherein the functionality is thermostability and the means for improving comprises proline substituted at position 8.

3. The nucleic acid molecule of claim 2 wherein the means for improving further comprises the helix-capping mutation defined as an arginine or aspartic acid residue substituted at a position selected from the group consisting of position 64, 337, 327, 405, 410, and any combination thereof.

4. The nucleic acid molecule of claim 2 wherein the means for improving further comprises substitution of glycine at position 99.

5. A method for mutating a nucleic acid encoding a wild type cellobiohydrolase of SEQ ID NO: 99, the method comprising mutating the wild type cellobiohydrolase with proline substituted at position 8.

6. The method of claim 5 , wherein the mutation further comprises substitution of a non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384, and any combination thereof.

7. The method of claim 5 , wherein the step of mutating comprises site-directed mutagenesis.

8. The method of claim 5 , further comprising a step of shortening a linker region of the wild-type cellobiohydrolase with respect to wild-type linker region SEQ ID NO: 2 to provide a linker region having a length of from about 6 amino acids to about 17 amino acids located between a catalytic domain and a cellulose binding domain (CBD) of SEQ ID NO: 99.

9. The nucleic acid molecule of claim 2 wherein the functionality is thermostability and the means for improving further comprises substitution of a cysteine at positions 197 and 370.

10. The nucleic acid molecule of claim 2 wherein the functionality is thermostability and the means for improving further comprises substitution of a non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384, and any combination thereof.

11. The nucleic acid molecule of claim 2 wherein the functionality is thermostability and the means for improving further comprises substitution of an alanine at a position selected from the group consisting of position 45, 270, 384, and any combination thereof.

12. The nucleic acid molecule of claim 1 , wherein the variant cellobiohydrolase comprises a linker region having a length of from about 6 amino acids to about 17 amino acids located between a catalytic domain and a cellulose binding domain (CBD) and wherein the variant cellobiohydrolase comprises a proline substituted at position 8 relative to SEQ ID NO: 99.

13. A nucleic acid molecule having a nucleic acid sequence encoding a variant cellobiohydrolase mutated with respect to a wild-type cellobiohydrolase of SEQ ID NO: 99, the mutation comprising proline substituted in the place of the serine at position 8.

14. The nucleic acid molecule of claim 1 wherein the means for improving functionality comprises means for enhancing thermostability.

15. The nucleic acid molecule of claim 13 , wherein the variant cellobiohydrolase is further mutated with a mutation selected from the group consisting of:

(a) proline substituted at a position selected from the group consisting of position 27, 43, 75, 94, 190, 195, 287, 299, 312, 315, 359, 398, 401, 414, 431, 433, and any combination thereof;

(b) a helix-capping mutation defined as an arginine or aspartic acid residue substituted at a position selected from the group consisting of position 64, 337, 327, 405, 410 and any combination thereof;

(c) substitution of glycine at position 99;

(d) substitution of cysteine at positions 197 and 370;

(e) substitution of a non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 684 and any combination thereof,

(f) alanine substitution at a position selected from the group consisting of position 45, 270, 384 and any combination thereof; and

(g) any combination of the mutations of (a), (b), (c), (d), (e), (f),

wherein the positional reference is within the amino acid sequence of the wild-type cellobiohydrolase SEQ ID NO: 99.

16. A nucleic acid molecule having a nucleic acid sequence encoding a variant cellobiohydrolase mutated with respect to a wild-type cellobiohydrolase represented by SEQ ID NO: 99, wherein the mutation comprises a proline substituted at position 8, and wherein the proline substitution improves the functionality of the variant cellobiohydrolase with respect to the wild-type cellobiohydrolase by improving thermostability.

17. The nucleic acid molecule of claim 16 wherein the mutation further comprises an arginine or aspartic acid residue substituted at a position selected from the group consisting of position 64, 337, 327, 405, 410, and any combination thereof.

18. The nucleic acid molecule of claim 16 wherein the mutation further comprises substitution of glycine at position 99.

19. The nucleic acid molecule of claim 16 wherein the mutation further comprises substitution of a cysteine at positions 197 and 370.

20. The nucleic acid molecule of claim 16 wherein the mutation further comprises substitution of a non-glycosyl accepting amino acid residue in place of an N-glycosylation site amino acid residue at a position selected from the group consisting of position 45, 270, 384, and any combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2008
From: MIDWEST RESEARCH INSTITUTE
To: ALLIANCE FOR SUSTAINABLE ENERGY, LLC
Reel/Frame 021603/0337 →